New study aims to help head and neck cancer patients complete Life-Saving treatment
NCT ID NCT04528420
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether early nutritional and medical support helps people with head and neck cancer complete their full course of radiation and chemotherapy. Many patients struggle to finish treatment due to weight loss and side effects. The study will enroll 138 adults and measure weight loss and survival rates.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 138 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2020
- Expected to finish
-
Jun 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male or female, over 18 and under 75 years of age, * Worl Health Organisation score \< 2, * Treatment for a localized squamous cell carcinoma of the head and neck for which a curative treatment by concomitant post-operative radiochemotherapy based on cisplatin is retained, * Having signed the informed consent, * Affiliate or beneficiary of a social protection scheme. Exclusion Criteria: * History of other neoplastic disease less than 2 years old or progressive, * History of radiotherapy for head and neck cancer, * Contraindications to cisplatin, * Pregnant or breastfeeding woman, * Protected major (under guardianship or curatorship), * Patient participating in a therapeutic study * Patient unable to understand the study for any reason or to comply with the constraints of the trial
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Squamous cell carcinoma of head and neck are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
7 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CH Beauvais
RECRUITINGBeauvais, France
-
CH Saint-Quentin
RECRUITINGSaint-Quentin, France
-
CHRU Lille
RECRUITINGLille, France
-
CHU Amiens
RECRUITINGAmiens, France
-
Centre Guillaume le Conquérant
RECRUITINGLe Havre, France
-
Centre Henri Becquerel
RECRUITINGRouen, France
-
Clinique du Parc
NOT_YET_RECRUITINGCaen, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Shorter radiation course tested for advanced head and neck cancer
- Can an experimental drug shrink advanced solid tumors?
- Smartphone app aims to combat malnutrition in head and neck cancer patients
- Can adding radiation boost immunotherapy against spread head and neck cancer?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- New hope for hard-to-treat cancers? experimental combo enters phase 2 trial